GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Change In Prepaid Assets

OmniAb (OmniAb) Change In Prepaid Assets : $1.94 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OmniAb Change In Prepaid Assets?

OmniAb's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was $0.41 Mil. It means OmniAb's Prepaid Assets increased by $0.41 Mil from Dec. 2023 to Mar. 2024 .

OmniAb's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $2.32 Mil. It means OmniAb's Prepaid Assets increased by $2.32 Mil from Dec. 2022 to Dec. 2023 .


OmniAb Change In Prepaid Assets Historical Data

The historical data trend for OmniAb's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Change In Prepaid Assets Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Prepaid Assets
- - -0.63 -4.71 2.32

OmniAb Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 1.43 0.09 0.01 0.41

OmniAb Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OmniAb Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of OmniAb's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


OmniAb (OmniAb) Business Description

Industry
Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Executives
Matthew W Foehr director, officer: President & CEO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love director C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean director, 10 percent owner 65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson officer: EVP, Finance and CFO 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce director C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010